Postsurgical Therapeutics

Executive Summary

Postsurgical Therapeutics is a preclinical-stage pharmaceutical company leveraging a proprietary PLGA-based drug delivery system (DDS) to reformulate FDA-approved drugs for new therapeutic indications. The company’s technology enables sustained, localized drug release, minimizing systemic side effects while maximizing efficacy at the target site. This approach is particularly suited for postsurgical pain management, where prolonged analgesia without opioid-related adverse events could address a significant unmet need. Founded in 2014 and based in San Francisco, the company remains private with no disclosed funding or valuation. Its strategy of repurposing approved drugs reduces regulatory risk and development timelines, though it remains at an early-stage with limited public data. The platform's versatility allows for application across multiple therapeutic areas, but the company's current focus appears to be on postsurgical indications. While the PLGA-based DDS has well-established precedent in long-acting injectables, clinical translation requires demonstration of safety and efficacy in human trials. Postsurgical Therapeutics faces challenges common to preclinical companies, including securing financing for IND-enabling studies and navigating competitive landscape of non-opioid pain therapies. However, the potential to create differentiated products with favorable risk-benefit profiles supports cautious optimism.

Upcoming Catalysts (preview)

• TBDLead Candidate Selection for Postsurgical Pain40% success
• TBDPreclinical Efficacy Data for PLGA-based Formulation35% success